Developer docs
API playgroundTry for free, no card

Search company profiles

Alafair Biosciences

Full company profile

uuid0000ds4

Namestring
Alafair Biosciences
Legal namestring
Alafair Biosciences, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Alafair Biosciences, Inc. is a privately held medical device company headquartered in Austin, Texas, that develops, manufactures, and commercializes bioresorbable soft-tissue protection devices built on its proprietary VersaCore Hydrogel Technology platform. The platform combines naturally derived high-molecular-weight hyaluronic acid and alginate into a collagen-free, dye-free, selectively permeable hydrogel that provides a protective gliding surface between adjacent tissue planes to prevent postoperative tethering and scar-tissue adherence. The commercial portfolio consists of VersaWrap Hydrogel Sheet (an ultrathin, sutureless, conformable sheet FDA-cleared in 2016 for tendon and in 2020 for peripheral nerve), the VersaWrap Application Kit (which converts a sheet into syringe-deliverable gel), and VersaCoat Flowable Hydrogel (a ready-to-use syringe-deliverable gel FDA-cleared in July 2025 and commercially launched in June 2026). The technology is protected by 23 granted US patents.

The company serves US-based orthopedic, upper-extremity, spine, and plastic and reconstructive surgeons performing tendon repair, ligament repair, skeletal muscle protection, and peripheral nerve procedures across hospitals, surgical centers, and physician offices. As of June 2026, VersaWrap Hydrogel Sheet had been implanted in more than 40,000 patients. The business model is one-time hardware sales per surgical case, distributed through a direct field sales organization with a dedicated field reimbursement team (supporting prior authorizations and appeals) and an independent distributor network managed via a distributor portal. Pricing is quote-based and not publicly disclosed. The company holds GPO agreements with Premier, Inc. (2024) and an Innovative Technology Contract with Vizient (2025), and is generating indication-expanding evidence through multi-center clinical studies including the B.R.A.A.D study for Achilles tendon repair (enrollment initiated June 2025 at UC Davis).

Alafair has achieved 722% three-year revenue growth and has appeared on the Inc. 5000 list for three consecutive years (No. 574 in 2025, up 254 spots). It is led by co-founder John Joyoprayitno (President & CEO) alongside co-founders Sarah Mayes PhD (CSO) and Dan Peterson MD, with a commercial-heavy C-suite drawn from Zimmer Biologics, Medtronic, NuVasive, Stryker (via Orthovita), and Novartis. The company has been recognized on Inc.'s Best Workplaces lists (2025 and 2026) and the co-founding team was named a finalist for the EY Entrepreneur Of The Year 2026 Gulf South Award.

Short descriptiontext

Alafair Biosciences is an Austin, Texas–based private medical device company that develops FDA-cleared, bioresorbable hyaluronic-acid and alginate hydrogel devices (VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel) used by orthopedic, spine, and reconstructive surgeons to prevent postoperative soft-tissue tethering and adhesion in tendon, ligament, muscle, and nerve procedures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
soft-tissue protection devices, bioresorbable hydrogel implants, postoperative adhesion prevention, hyaluronic acid biomaterials, orthopedic surgical devices
Industry1 code
PRIMARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Soft-Tissue Protection Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Alafair generates revenue through the sale of its FDA-cleared medical devices including VersaWrap Hydrogel Sheet and VersaCoat Flowable Hydrogel. Products are sold directly to healthcare facilities and through distributor networks as one-time surgical products with no recurring revenue from customers.

alafairbiosciences.com
2Reimbursement Support Services
TypeProfessional Services
Description

The company provides field reimbursement support services including prior authorization assistance and appeals support for patients, which complements product sales to healthcare facilities.

alafairbiosciences.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Quote-based pricing for VersaWrap and VersaCoat products
ModelOtherBilling cadencePay-as-you-go
Notes

No public pricing available. Contact form required for pricing information.

alafairbiosciences.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1VersaCore
Description

Proprietary naturally-derived biopolymer platform technology behind the company's soft-tissue protection portfolio, combining hyaluronic acid and alginate

alafairbiosciences.com
+2 more records
Core offering1 text field

Alafair Biosciences develops and commercializes FDA-cleared, bioresorbable hydrogel medical devices for protecting tendon, ligament, skeletal muscle, and peripheral nerve tissues during surgical repair. Its current portfolio includes VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel, and the VersaWrap Application Kit, all based on the proprietary VersaCore platform for maintaining a protective gliding surface and reducing postoperative tethering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 40,000+ implants with VersaWrap Hydrogel Sheet demonstrating clinical adoption and safety profile
+3 more records
Product overview1 text field

Alafair Biosciences offers a portfolio of FDA-cleared bioresorbable medical devices built on the proprietary VersaCore Hydrogel Technology platform. The portfolio consists of VersaWrap Hydrogel Sheet (a conformable, sutureless sheet that can also be converted to gel format using the VersaWrap Application Kit) and VersaCoat Flowable Hydrogel (a ready-to-use syringe-deliverable gel). Both products are based on naturally-derived hyaluronic acid and alginate, providing protective gliding surfaces to prevent postoperative tethering during tendon, ligament, muscle, and nerve repair procedures.

Product and service3 records
1VersaCoat™ Flowable Hydrogel
CategorySoft-Tissue Protection Medical Device
Description

A syringe-deliverable, bioresorbable soft-tissue protection device that forms a tissue-adherent gel layer and sustained gliding surface to reduce postoperative tethering. It is cleared for tendon, ligament, skeletal muscle, and peripheral nerve applications and is available in 1 mL and 2 mL volumes.

2VersaWrap® Hydrogel Sheet
CategorySoft-Tissue Protection Medical Device
Description

A conformable, sutureless, non-swelling, bioresorbable hydrogel sheet that provides a sustained gliding surface between opposing tissues to reduce friction and postoperative tethering. It is cleared for tendon, ligament, skeletal muscle, and peripheral nerve applications and is available in 1x2 inch and 2x2 inch sizes.

3VersaWrap® Application Kit
CategoryMedical Device Application Accessory
Description

An accessory kit that converts a 5x5 cm VersaWrap Hydrogel Sheet into 0.5 mL of syringe-deliverable gel for targeted application in complex or difficult-to-access anatomical sites. The kit includes syringes, a connector, and wetting solution.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Alafair Biosciences was awarded a Synthetic Implantable Products Agreement with Premier, Inc. for VersaWrap Hydrogel Sheet. This GPO agreement provides access to Alafair's products through Premier's network of healthcare facilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Alafair Biosciences received an Innovative Technology Contract from Vizient for VersaWrap. The company exhibited at the Vizient Innovative Technology Exchange, positioning VersaWrap as an innovative technology for Vizient member hospitals.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Anika develops hyaluronic acid-based medical products for orthopedic, sports medicine, and wound healing applications. Alafair's hyaluronic acid/alginate VersaCore hydrogel addresses the same anti-adhesion and soft-tissue protection use cases Anika targets with its viscosupplementation and regenerative franchises.

TypeBroad incumbent
Description

Arthrex is the dominant privately held sports medicine and orthopedic soft-tissue repair company, selling anchors, grafts, and biologic adjuncts. While Arthrex does not sell a direct hydrogel anti-adhesion equivalent, it controls the surgeon relationships and procedural channels where VersaWrap and VersaCoat are adopted.

TypeBroad incumbent
Description

Smith+Nephew's Sports Medicine franchise sells tendon repair implants, anchors, and regenerative scaffolds in the same procedures where Alafair's hydrogel sheet is used. As a broad incumbent it can bundle or compete against VersaWrap/VersaCoat in hospital contracts.

TypeBroad incumbent
Description

Stryker (including its Orthovita sports medicine heritage, where Alafair's CMO previously worked) offers orthopedic biologics and soft-tissue repair products. As a large incumbent, Stryker has the surgeon access and capital to compete in the anti-adhesion space.

TypeBroad incumbent
Description

Integra manufactures regenerative wound dressings, skin substitutes, and surgical implants for soft-tissue repair. Its regenerative wound healing and dural repair products overlap with Alafair's soft-tissue protection use cases in surgical settings.

TypeBroad incumbent
Description

Conmed's orthopedic/sports medicine portfolio includes tissue repair devices, anchors, and surgical consumables used in the same tendon and ligament procedures where VersaWrap is adopted. It competes for hospital budget allocation and surgeon loyalty.

TypeEmerging player
Description

MiMedx markets placental tissue allografts for wound healing, soft-tissue recovery, and surgical applications. It targets adjacent regenerative and tissue protection use cases to Alafair's VersaCore platform.

TypeEmerging player
Description

Organogenesis develops regenerative skin and soft-tissue products including advanced wound care dressings and surgical biologics. It competes in adjacent regenerative surgery markets where anti-adhesion and soft-tissue protection are relevant.

TypeEmerging player
Description

Isto Biologics develops orthobiologic products for spine, sports medicine, and orthopedic surgery, including bone graft substitutes and soft-tissue repair scaffolds. It overlaps with Alafair's tendon, ligament, and surgical soft-tissue applications.

TypeEmerging player
Description

Bioventus offers orthobiologic solutions for pain management, joint preservation, and surgical recovery. Its surgical recovery and regenerative products compete in adjacent orthopedic soft-tissue healing indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alafair Biosciences

Soft-Tissue Protection Medical Devicesalafairbiosciences.com

Alafair Biosciences is an Austin, Texas–based private medical device company that develops FDA-cleared, bioresorbable hyaluronic-acid and alginate hydrogel devices (VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel) used by orthopedic, spine, and reconstructive surgeons to prevent postoperative soft-tissue tethering and adhesion in tendon, ligament, muscle, and nerve procedures.

What Alafair Biosciences does

Alafair Biosciences, Inc. is a privately held medical device company headquartered in Austin, Texas, that develops, manufactures, and commercializes bioresorbable soft-tissue protection devices built on its proprietary VersaCore Hydrogel Technology platform. The platform combines naturally derived high-molecular-weight hyaluronic acid and alginate into a collagen-free, dye-free, selectively permeable hydrogel that provides a protective gliding surface between adjacent tissue planes to prevent postoperative tethering and scar-tissue adherence. The commercial portfolio consists of VersaWrap Hydrogel Sheet (an ultrathin, sutureless, conformable sheet FDA-cleared in 2016 for tendon and in 2020 for peripheral nerve), the VersaWrap Application Kit (which converts a sheet into syringe-deliverable gel), and VersaCoat Flowable Hydrogel (a ready-to-use syringe-deliverable gel FDA-cleared in July 2025 and commercially launched in June 2026). The technology is protected by 23 granted US patents.

The company serves US-based orthopedic, upper-extremity, spine, and plastic and reconstructive surgeons performing tendon repair, ligament repair, skeletal muscle protection, and peripheral nerve procedures across hospitals, surgical centers, and physician offices. As of June 2026, VersaWrap Hydrogel Sheet had been implanted in more than 40,000 patients. The business model is one-time hardware sales per surgical case, distributed through a direct field sales organization with a dedicated field reimbursement team (supporting prior authorizations and appeals) and an independent distributor network managed via a distributor portal. Pricing is quote-based and not publicly disclosed. The company holds GPO agreements with Premier, Inc. (2024) and an Innovative Technology Contract with Vizient (2025), and is generating indication-expanding evidence through multi-center clinical studies including the B.R.A.A.D study for Achilles tendon repair (enrollment initiated June 2025 at UC Davis).

Alafair has achieved 722% three-year revenue growth and has appeared on the Inc. 5000 list for three consecutive years (No. 574 in 2025, up 254 spots). It is led by co-founder John Joyoprayitno (President & CEO) alongside co-founders Sarah Mayes PhD (CSO) and Dan Peterson MD, with a commercial-heavy C-suite drawn from Zimmer Biologics, Medtronic, NuVasive, Stryker (via Orthovita), and Novartis. The company has been recognized on Inc.'s Best Workplaces lists (2025 and 2026) and the co-founding team was named a finalist for the EY Entrepreneur Of The Year 2026 Gulf South Award.

Alafair Biosciences firmographics

Firmographics
Name
Alafair Biosciences
Legal name
Alafair Biosciences, Inc.
Website
https://alafairbiosciences.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Alafair Biosciences is an Austin, Texas–based private medical device company that develops FDA-cleared, bioresorbable hyaluronic-acid and alginate hydrogel devices (VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel) used by orthopedic, spine, and reconstructive surgeons to prevent postoperative soft-tissue tethering and adhesion in tendon, ligament, muscle, and nerve procedures.
Ownership category
akta.pro rank

Alafair Biosciences industry classification

Industry
Product category
Soft-Tissue Protection Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Soft-tissue protection devices
  • Bioresorbable hydrogel implants
  • Postoperative adhesion prevention
  • Hyaluronic acid biomaterials
  • Orthopedic surgical devices

Where Alafair Biosciences is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alafair Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Medical Device Sales: Alafair generates revenue through the sale of its FDA-cleared medical devices including VersaWrap Hydrogel Sheet and VersaCoat Flowable Hydrogel. Products are sold directly to healthcare facilities and through distributor networks as one-time surgical products with no recurring revenue from customers.
  2. Reimbursement Support Services: The company provides field reimbursement support services including prior authorization assistance and appeals support for patients, which complements product sales to healthcare facilities.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for VersaWrap and VersaCoat products

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Alafair Biosciences product offering

Product offering

Core offering

Alafair Biosciences develops and commercializes FDA-cleared, bioresorbable hydrogel medical devices for protecting tendon, ligament, skeletal muscle, and peripheral nerve tissues during surgical repair. Its current portfolio includes VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel, and the VersaWrap Application Kit, all based on the proprietary VersaCore platform for maintaining a protective gliding surface and reducing postoperative tethering.

Product overview

Alafair Biosciences offers a portfolio of FDA-cleared bioresorbable medical devices built on the proprietary VersaCore Hydrogel Technology platform. The portfolio consists of VersaWrap Hydrogel Sheet (a conformable, sutureless sheet that can also be converted to gel format using the VersaWrap Application Kit) and VersaCoat Flowable Hydrogel (a ready-to-use syringe-deliverable gel). Both products are based on naturally-derived hyaluronic acid and alginate, providing protective gliding surfaces to prevent postoperative tethering during tendon, ligament, muscle, and nerve repair procedures.

Differentiator

Problem solved

Functional benefit

Brands

  • VersaCore: Proprietary naturally-derived biopolymer platform technology behind the company's soft-tissue protection portfolio, combining hyaluronic acid and alginate
  • VersaWrap
  • VersaCoat

Products and services

  • VersaCoat™ Flowable Hydrogel A syringe-deliverable, bioresorbable soft-tissue protection device that forms a tissue-adherent gel layer and sustained gliding surface to reduce postoperative tethering. It is cleared for tendon, ligament, skeletal muscle, and peripheral nerve applications and is available in 1 mL and 2 mL volumes.
  • VersaWrap® Hydrogel Sheet A conformable, sutureless, non-swelling, bioresorbable hydrogel sheet that provides a sustained gliding surface between opposing tissues to reduce friction and postoperative tethering. It is cleared for tendon, ligament, skeletal muscle, and peripheral nerve applications and is available in 1x2 inch and 2x2 inch sizes.
  • VersaWrap® Application Kit An accessory kit that converts a 5x5 cm VersaWrap Hydrogel Sheet into 0.5 mL of syringe-deliverable gel for targeted application in complex or difficult-to-access anatomical sites. The kit includes syringes, a connector, and wetting solution.

Quantifiable outcome

  • 40,000+ implants with VersaWrap Hydrogel Sheet demonstrating clinical adoption and safety profile
  • +3 more outcomes

Companies that use Alafair Biosciences

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Alafair Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alafair Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Premier, Inc.coreStrategic or Co-development Partner · 1 January 2024Alafair Biosciences was awarded a Synthetic Implantable Products Agreement with Premier, Inc. for VersaWrap Hydrogel Sheet. This GPO agreement provides access to Alafair's products through Premier's network of healthcare facilities.
  • VizientcoreStrategic or Co-development Partner · 1 January 2024Alafair Biosciences received an Innovative Technology Contract from Vizient for VersaWrap. The company exhibited at the Vizient Innovative Technology Exchange, positioning VersaWrap as an innovative technology for Vizient member hospitals.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Alafair Biosciences competitors and assessment

Company assessment

Direct peers

  • Anika Therapeutics: Anika develops hyaluronic acid-based medical products for orthopedic, sports medicine, and wound healing applications. Alafair's hyaluronic acid/alginate VersaCore hydrogel addresses the same anti-adhesion and soft-tissue protection use cases Anika targets with its viscosupplementation and regenerative franchises.

Broad incumbents

  • Arthrex: Arthrex is the dominant privately held sports medicine and orthopedic soft-tissue repair company, selling anchors, grafts, and biologic adjuncts. While Arthrex does not sell a direct hydrogel anti-adhesion equivalent, it controls the surgeon relationships and procedural channels where VersaWrap and VersaCoat are adopted.
  • Smith+Nephew: Smith+Nephew's Sports Medicine franchise sells tendon repair implants, anchors, and regenerative scaffolds in the same procedures where Alafair's hydrogel sheet is used. As a broad incumbent it can bundle or compete against VersaWrap/VersaCoat in hospital contracts.
  • Stryker: Stryker (including its Orthovita sports medicine heritage, where Alafair's CMO previously worked) offers orthopedic biologics and soft-tissue repair products. As a large incumbent, Stryker has the surgeon access and capital to compete in the anti-adhesion space.
  • Integra LifeSciences: Integra manufactures regenerative wound dressings, skin substitutes, and surgical implants for soft-tissue repair. Its regenerative wound healing and dural repair products overlap with Alafair's soft-tissue protection use cases in surgical settings.
  • Conmed: Conmed's orthopedic/sports medicine portfolio includes tissue repair devices, anchors, and surgical consumables used in the same tendon and ligament procedures where VersaWrap is adopted. It competes for hospital budget allocation and surgeon loyalty.

Emerging players

  • MiMedx: MiMedx markets placental tissue allografts for wound healing, soft-tissue recovery, and surgical applications. It targets adjacent regenerative and tissue protection use cases to Alafair's VersaCore platform.
  • Organogenesis: Organogenesis develops regenerative skin and soft-tissue products including advanced wound care dressings and surgical biologics. It competes in adjacent regenerative surgery markets where anti-adhesion and soft-tissue protection are relevant.
  • Isto Biologics: Isto Biologics develops orthobiologic products for spine, sports medicine, and orthopedic surgery, including bone graft substitutes and soft-tissue repair scaffolds. It overlaps with Alafair's tendon, ligament, and surgical soft-tissue applications.
  • Bioventus: Bioventus offers orthobiologic solutions for pain management, joint preservation, and surgical recovery. Its surgical recovery and regenerative products compete in adjacent orthopedic soft-tissue healing indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Alafair Biosciences social profiles

Digital presence

Alafair Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alafair Biosciences leadership team

Management profile

Number of profiles

Profiles7 records

Alafair Biosciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alafair Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alafair Biosciences

What does Alafair Biosciences do?

Alafair Biosciences develops and commercializes FDA-cleared, bioresorbable hydrogel medical devices for protecting tendon, ligament, skeletal muscle, and peripheral nerve tissues during surgical repair. Its current portfolio includes VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel, and the VersaWrap Application Kit, all based on the proprietary VersaCore platform for maintaining a protective gliding surface and reducing postoperative tethering.

Is Alafair Biosciences a public or private company?

Alafair Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alafair Biosciences founded?

Alafair Biosciences was founded in 2016. It employs 51 to 100 people.

Where is Alafair Biosciences based?

Alafair Biosciences is headquartered in Austin, United States, in the North America region.

How does Alafair Biosciences make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are reimbursement Support Services.

Who are Alafair Biosciences's main competitors?

Anika Therapeutics is listed as a direct peer. Broad incumbents are Arthrex, Smith+Nephew, Stryker, Integra LifeSciences and Conmed. Emerging players are MiMedx, Organogenesis, Isto Biologics and Bioventus.

Does Alafair Biosciences have an API?

No public API is recorded for Alafair Biosciences.

What industry is Alafair Biosciences in?

Alafair Biosciences's product category is Soft-Tissue Protection Medical Devices. Its primary akta.pro industry code is HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAlafair Biosciences Named to the 2026 Inc. 5000, Marking 4th Consecutive Year on the ListAlafair Biosciences has been named to the 2026 Inc. 5000 list for the fourth consecutive year, recognizing its rapid growth as a private medical device company based in Austin, Texas. This recognition coincides with the recent launch of VersaCoat™ Flowable Hydrogel, an expansion of the company's soft-tissue protection portfolio that utilizes its proprietary VersaCore™ technology.PR NewswireAlafair Biosciences Announces Launch of VersaCoat™ Flowable HydrogelAlafair Biosciences announced the launch of VersaCoat™ Flowable Hydrogel, a syringe-deliverable bioresorbable soft-tissue protector for orthopedic surgery. The new product extends the company's existing VersaCore™ Hydrogel Technology platform to anatomically complex surgical sites where precise placement is needed, building on the clinical success of their VersaWrap® Hydrogel Sheet which has been used in over 40,000 implants. Early commercial experience with VersaCoat exceeded expectations, supporting plans to scale adoption across a broader range of procedures.American City Business JournalsAlafair Biosciences is one of Austin's Best Places to WorkAlafair Biosciences has been recognized as one of Austin's Best Places to Work in 2026 by the Austin Business Journal. The recognition highlights the company's workplace culture and environment within the local business community.PR NewswireJohn Joyoprayitno, Sarah Mayes, PhD, and Dan Peterson, MD Named Finalists for Entrepreneur Of The Year® 2026 Gulf South AwardCo-founders John Joyoprayitno, Sarah Mayes, PhD, and Dan Peterson, MD of Alafair Biosciences have been named finalists for the Entrepreneur Of The Year 2026 Gulf South Award by Ernst & Young LLP (EY US), now in its 41st year. The award celebrates bold leaders whose vision and innovation shape the future of business, recognizing finalists for entrepreneurial spirit, purpose-driven leadership, company growth, and long-term value creation. Winners will be announced at a later date.PR NewswireAlafair Biosciences' President & CEO and Co-Founder, John Joyoprayitno, Named to Inc.'s Business Leader of the Year List; Company Also Earns Spot on Inc.'s Best in Business ListAlafair Biosciences announced that its President & CEO and Co-Founder, John Joyoprayitno, has been named to Inc.'s Business Leader of the Year list, while the company itself was selected for the 2025 Inc. Best in Business List. This recognition highlights the firm's exceptional 722% year-over-year growth and its strategic expansion, which includes selling over 35,000 VersaWrap implants and launching the new VersaCoat Flowable Hydrogel product.PR NewswireWith 722% Revenue Growth Over Three Years, Alafair Biosciences Celebrates Its Third Appearance on the Inc. 5000 ListAlafair Biosciences moved up 254 spots to rank No. 574 on the 2025 Inc. 5000 list of fastest-growing private companies in America, marking its third appearance on the list with 722% revenue growth over three years. The company recently received two FDA 510(k) clearances for VersaCoat Tendon Protector and VersaCoat Nerve Protector, marketed together as VersaCoat Flowable Hydrogel, a syringe-deliverable gel designed to protect soft tissues and reduce post-operative tethering in orthopedic surgery patients.PR NewswireAlafair Biosciences Receives 510(k) Clearance for VersaCoat™ Tendon Protector and VersaCoat™ Nerve ProtectorAlafair Biosciences, a medical device company based in Austin, Texas, announced receipt of two FDA 510(k) clearances for VersaCoat Tendon Protector and VersaCoat Nerve Protector, marketed together as VersaCoat Flowable Hydrogel. The product is a syringe-deliverable hyaluronic acid and alginate gel designed to provide protective gliding surfaces that limit post-operative tethering in orthopedic and nerve surgeries. The company stated the new flowable format addresses surgeon feedback for treating larger, more complex injuries and enables delivery to hard-to-reach tissues, building on the success of its existing VersaWrap Hydrogel Sheet which has achieved over 30,000 implants.PR NewswireAlafair Biosciences Named to Inc.'s 2025 Best Workplaces ListAlafair Biosciences, a privately held medical device company based in Austin, Texas, has been named to Inc.'s 2025 Best Workplaces list, an award determined through employee surveys conducted by Quantum Workplace covering management effectiveness, perks, and professional development. The company, which manufactures the FDA-cleared VersaWrap Hydrogel Sheet for tendon and nerve repair procedures, has achieved over 27,000 implants in the United States and reported industry-leading revenue growth. The recognition reinforces Alafair's stated belief that investing in its workforce supports its mission to expand surgeon adoption of its products and advance surgical outcomes.PR NewswireAlafair Biosciences Announces First Patient Enrolled in Multi-Center Study Evaluating VersaWrap® Tendon Protector for Achilles RepairAlafair Biosciences announced the enrollment of the first patient at UC Davis Foot and Ankle Orthopaedics Clinic in a prospective, multi-center clinical study evaluating VersaWrap for Achilles tendon repair. The B.R.A.A.D study will assess the device's effectiveness in reducing postoperative complications such as tendon tethering and scar tissue formation. VersaWrap is an FDA-cleared, bioresorbable hydrogel device made of hyaluronic acid and alginate designed to protect tendons and nerves during surgical procedures.ReviewedA Second Look at the Use of VersaWrap® Nerve Protector in Spine Surgery: A Case ReportAlafair Biosciences reported a retrospective case series of 169 lumbar decompression procedures using its VersaWrap Nerve Protector in conjunction with Depo-Medrol and Marcaine/epinephrine, finding zero complications. A representative revision surgery confirmed that the hydrogel bioresorbed completely and allowed for easy scar tissue removal without mechanical disruption. The findings suggest this combination offers a promising approach to managing epidural fibrosis in spine surgery.